The implications of sarcopenia and sarcopenic obesity on cardiometabolic disease

Tae Nyun Kim, Kyung Mook Choi

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The important changes in body composition associated with aging are a decline in skeletal muscle mass and an increase in body fat. Body fat distribution also changes with age; subcutaneous fat decreases and visceral abdominal fat increase, which contributes to numerous cardiometabolic diseases (CMDs) such as type 2 diabetes, dyslipidemia, and cardiovascular disease (CVD). Sarcopenia often accompanied by an increase in body fat and vice versa, a scenario termed sarcopenic obesity (SO), which might lead to the cumulative risk of both sarcopenia and obesity. However, there is still no consensus regarding the definition and consequences of SO. The lack of a unified definition for SO might contribute to inconsistent findings about the association of SO with CMD. Complex etiologies are associated with development of SO. A vicious cycle between the loss of muscle and the accumulation of ectopic fat might be associated with CMD via an intricate interplay of factors including proinflammatory cytokines, oxidative stress, mitochondrial dysfunction, insulin resistance, dietary energy, physical activity, mitochondrial dysfunction, and other factors that have yet to be identified. Moreover, recent epidemiological studies suggest that SO is related to CVD and mortality. This review focuses on the current literature with regard to the association between sarcopenia, dynapenia, and obesity, as well as their implications for CMD. The ultimate goal of this Prospects is to encourage conduct of well-designed future studies that elucidate the relationship among sarcopenia, SO, and CMD. J. Cell. Biochem. 116: 1171-1178, 2015.

Original languageEnglish
Pages (from-to)1171-1178
Number of pages8
JournalJournal of Cellular Biochemistry
Volume116
Issue number7
DOIs
Publication statusPublished - 2015 Jul 1

Fingerprint

Sarcopenia
Obesity
Fats
Muscle
Association reactions
Adipose Tissue
Cardiovascular Diseases
Oxidative stress
Medical problems
Body Fat Distribution
Intra-Abdominal Fat
Subcutaneous Fat
Dyslipidemias
Body Composition
Aging of materials
Type 2 Diabetes Mellitus
Insulin
Cytokines
Insulin Resistance
Epidemiologic Studies

Keywords

  • CARDIOMETABOLIC DISEASE
  • SARCOPENIA
  • SARCOPENIC OBESITY
  • VISCERAL OBESITY

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

The implications of sarcopenia and sarcopenic obesity on cardiometabolic disease. / Kim, Tae Nyun; Choi, Kyung Mook.

In: Journal of Cellular Biochemistry, Vol. 116, No. 7, 01.07.2015, p. 1171-1178.

Research output: Contribution to journalArticle

@article{7d6e7e65016f4acbaeb09cedf310ef6b,
title = "The implications of sarcopenia and sarcopenic obesity on cardiometabolic disease",
abstract = "The important changes in body composition associated with aging are a decline in skeletal muscle mass and an increase in body fat. Body fat distribution also changes with age; subcutaneous fat decreases and visceral abdominal fat increase, which contributes to numerous cardiometabolic diseases (CMDs) such as type 2 diabetes, dyslipidemia, and cardiovascular disease (CVD). Sarcopenia often accompanied by an increase in body fat and vice versa, a scenario termed sarcopenic obesity (SO), which might lead to the cumulative risk of both sarcopenia and obesity. However, there is still no consensus regarding the definition and consequences of SO. The lack of a unified definition for SO might contribute to inconsistent findings about the association of SO with CMD. Complex etiologies are associated with development of SO. A vicious cycle between the loss of muscle and the accumulation of ectopic fat might be associated with CMD via an intricate interplay of factors including proinflammatory cytokines, oxidative stress, mitochondrial dysfunction, insulin resistance, dietary energy, physical activity, mitochondrial dysfunction, and other factors that have yet to be identified. Moreover, recent epidemiological studies suggest that SO is related to CVD and mortality. This review focuses on the current literature with regard to the association between sarcopenia, dynapenia, and obesity, as well as their implications for CMD. The ultimate goal of this Prospects is to encourage conduct of well-designed future studies that elucidate the relationship among sarcopenia, SO, and CMD. J. Cell. Biochem. 116: 1171-1178, 2015.",
keywords = "CARDIOMETABOLIC DISEASE, SARCOPENIA, SARCOPENIC OBESITY, VISCERAL OBESITY",
author = "Kim, {Tae Nyun} and Choi, {Kyung Mook}",
year = "2015",
month = "7",
day = "1",
doi = "10.1002/jcb.25077",
language = "English",
volume = "116",
pages = "1171--1178",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - The implications of sarcopenia and sarcopenic obesity on cardiometabolic disease

AU - Kim, Tae Nyun

AU - Choi, Kyung Mook

PY - 2015/7/1

Y1 - 2015/7/1

N2 - The important changes in body composition associated with aging are a decline in skeletal muscle mass and an increase in body fat. Body fat distribution also changes with age; subcutaneous fat decreases and visceral abdominal fat increase, which contributes to numerous cardiometabolic diseases (CMDs) such as type 2 diabetes, dyslipidemia, and cardiovascular disease (CVD). Sarcopenia often accompanied by an increase in body fat and vice versa, a scenario termed sarcopenic obesity (SO), which might lead to the cumulative risk of both sarcopenia and obesity. However, there is still no consensus regarding the definition and consequences of SO. The lack of a unified definition for SO might contribute to inconsistent findings about the association of SO with CMD. Complex etiologies are associated with development of SO. A vicious cycle between the loss of muscle and the accumulation of ectopic fat might be associated with CMD via an intricate interplay of factors including proinflammatory cytokines, oxidative stress, mitochondrial dysfunction, insulin resistance, dietary energy, physical activity, mitochondrial dysfunction, and other factors that have yet to be identified. Moreover, recent epidemiological studies suggest that SO is related to CVD and mortality. This review focuses on the current literature with regard to the association between sarcopenia, dynapenia, and obesity, as well as their implications for CMD. The ultimate goal of this Prospects is to encourage conduct of well-designed future studies that elucidate the relationship among sarcopenia, SO, and CMD. J. Cell. Biochem. 116: 1171-1178, 2015.

AB - The important changes in body composition associated with aging are a decline in skeletal muscle mass and an increase in body fat. Body fat distribution also changes with age; subcutaneous fat decreases and visceral abdominal fat increase, which contributes to numerous cardiometabolic diseases (CMDs) such as type 2 diabetes, dyslipidemia, and cardiovascular disease (CVD). Sarcopenia often accompanied by an increase in body fat and vice versa, a scenario termed sarcopenic obesity (SO), which might lead to the cumulative risk of both sarcopenia and obesity. However, there is still no consensus regarding the definition and consequences of SO. The lack of a unified definition for SO might contribute to inconsistent findings about the association of SO with CMD. Complex etiologies are associated with development of SO. A vicious cycle between the loss of muscle and the accumulation of ectopic fat might be associated with CMD via an intricate interplay of factors including proinflammatory cytokines, oxidative stress, mitochondrial dysfunction, insulin resistance, dietary energy, physical activity, mitochondrial dysfunction, and other factors that have yet to be identified. Moreover, recent epidemiological studies suggest that SO is related to CVD and mortality. This review focuses on the current literature with regard to the association between sarcopenia, dynapenia, and obesity, as well as their implications for CMD. The ultimate goal of this Prospects is to encourage conduct of well-designed future studies that elucidate the relationship among sarcopenia, SO, and CMD. J. Cell. Biochem. 116: 1171-1178, 2015.

KW - CARDIOMETABOLIC DISEASE

KW - SARCOPENIA

KW - SARCOPENIC OBESITY

KW - VISCERAL OBESITY

UR - http://www.scopus.com/inward/record.url?scp=84929093799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929093799&partnerID=8YFLogxK

U2 - 10.1002/jcb.25077

DO - 10.1002/jcb.25077

M3 - Article

C2 - 25545054

AN - SCOPUS:84929093799

VL - 116

SP - 1171

EP - 1178

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 7

ER -